Trials / Completed
CompletedNCT01097655
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Use of KALETRA® Tablets in Adult HIV-infected Patients: Data From the Multicenter Star/Stella Cohort
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,049 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients. In some patients, the study is to show the impact on tolerability of changing therapy to Kaletra tablets from other regimens.
Detailed description
This study was designed as a non-interventional observational study. Kaletra was prescribed in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines.
Conditions
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2010-04-02
- Last updated
- 2017-05-23
- Results posted
- 2017-05-23
Source: ClinicalTrials.gov record NCT01097655. Inclusion in this directory is not an endorsement.